Making the Investment Case for National Regulatory Authorities

Published : January 28, 2021

While the benefits of functional national regulatory authorities (NRAs) are diffused and often unseen, weak NRAs have serious, negative impacts. Championing the call for increased investment in NRAs to increase access to quality-assured medical products, MTaPS staff, Gloria Twesigye, Tamara Hafner, and Javier Guzman, co-authored a commentary, recently published in the Journal of Pharmaceutical Policy and Practice. The authors offer three arguments for greater investment in regulatory systems strengthening, focused on safeguarding public health; increasing health system’s efficiency; and bolstering local pharmaceutical manufacturing and trade.

Making the investment case for national regulatory authorities
By Gloria Twesigye, Tamara Hafner & Javier Guzman
Journal of Pharmaceutical Policy and Practice

Resources Focus Area: Regulatory Systems